In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.

Fifty-five volunteers treated with either intranasal recombinant interferon (rIFN; 2 x 10 6 IV/day) or placebo for 15 days were exposed to coronavirus by direct intranasal inoculation on the eighth day of treatment. Symptom scores were recorded, and cultures of virus were taken daily for all volunteers for seven days after inoculation. Nineteen (73%) of the 26 placebo recipients met symptom-score criteria for a cold, compared with 12 (41070) of the IFN recipients (P = .02). The mean nasal symptom scores in the placebo and IFN groups were 9.2 and 5.4, respectively (P = .03), and the mean total symptom scores in the two groups were 23.2 and 9.4, respectively (P = .003). The mean number of days with a total symptom score >4 was 1.6 in the placebo recipients and 0.5 in the rIFN recipients (P = .02). Prophylactic intranasal rIFN effectively shortened the duration and reduced the severity of coronavirus cold symptoms.
Prevention of Experimental Coronavirus Colds with Intranasal (l-2b Interferon

Background. In April 2012, the Jordan Ministry of Health investigated an outbreak of lower respiratory illnesses at a hospital in Jordan; 2 fatal cases were retrospectively confirmed by real-time reverse transcription polymerase chain reaction (rRT-PCR) to be the first detected cases of Middle East respiratory syndrome (MERS-CoV). Methods. Epidemiologic and clinical characteristics of selected potential cases were assessed through serum blood specimens, medical record reviews, and interviews with surviving outbreak members, household contacts, and healthcare personnel. Cases of MERS-CoV infection were identified using 3 US Centers for Disease Control and Prevention serologic tests for detection of anti-MERS-CoV antibodies. Results. Specimens and interviews were obtained from 124 subjects. Seven previously unconfirmed individuals tested positive for anti-MERS-CoV antibodies by at least 2 of 3 serologic tests, in addition to 2 fatal cases identified by rRT-PCR. The case-fatality rate among the 9 total cases was 22%. Six subjects were healthcare workers at the outbreak hospital, yielding an attack rate of 10% among potentially exposed outbreak hospital personnel. There was no evidence of MERS-CoV transmission at 2 transfer hospitals having acceptable infection control practices. Conclusions. Novel serologic tests allowed for the detection of otherwise unrecognized cases of MERS-CoV infection among contacts in a Jordanian hospital-associated respiratory illness outbreak in April 2012, resulting in a total of 9 test-positive cases. Serologic results suggest that further spread of this outbreak to transfer hospitals did not occur. Most subjects had no major, underlying medical conditions; none were on hemodialysis. Our observed casefatality rate was lower than has been reported from outbreaks elsewhere.
Eastern Mediterranean Public Health Network, and 6 Field Epidemiology Training Program

It is an exciting time in the field of microbiology because of the expansion of rapid diagnostic tests. Pathogen testing previously was performed by traditional laboratory methods such as bacterial, fungal, and viral culture or ova and parasite (O&P) examination. Testing could have a slow time to results; some testing lacked sensitivity, and most testing was centralized in the laboratory. Newer advances in pathogen detection assays are now providing rapid results and have greater sensitivity and specificity, and many assays are moving out of the centralized laboratory and to the patient as pointof-care tests. In this review, the authors chose to highlight the currently available US Food and Drug Administration (FDA)-cleared molecular assays for various infectious syndromes relevant to the pediatric population. Although outcome studies in this area are sparse, rapid results may result in decreased time to optimal antimicrobial treatment and improved patient outcomes. Disclosure Statement: E. McElvania is a consultant for Luminex Corporation. M.D. Gonzalez has no disclosures. KEYWORDS Rapid diagnostic assays Group A streptococcus Influenza RSV Syndromic multiplex panels Gastrointestinal panel Respiratory panel Meningitis encephalitis panel Compared with traditional rapid antigen testing, new diagnostics assays for Group A Streptococcus, influenza, and respiratory syncytial virus combine rapid turnaround time with high sensitivity and specificity. There has been a surge in the availability of multiplex syndromic panels that test for a broad range of pathogens associated with a single clinical presentation. Molecular infectious disease testing that was previously performed in microbiology laboratories is now being developed in easy-to-use platforms, which are available at point of care.
New Developments in Rapid Diagnostic Testing for Children